Compositions, methods and uses for alpha-1 antitrypsin fusion molecules
AssigneesKonkuk University, Omni Bio Pharmaceutical, Inc., The Regents of the University of Colorado, a body corporate
InventorsSoohyun Kim, Charles A. Dinarello, James D. Crapo
Life of this patent
Estimating the term…
Abstract
Compositions of and methods for making and using alpha-1 antitrypsin (AAT) fusion molecules or peptide derivatives thereof are disclosed. The compositions and methods relate to generating an AAT fusion molecule of use in pharmaceutically acceptable compositions to treat a subject in need of AAT therapy or treatment. Compositions and methods disclosed herein concern linking AAT or derivative thereof to an immune fragment.
Claims27
A construct comprising:
- a nucleic acid encoding alpha-1 antitrypsin (AAT) or fragment or peptide cleavage molecule thereof;
- and
- a nucleic acid encoding an immune fragment or a fragment capable of being joined to itself, the nucleic acid further manipulated to truncate or eliminate the immune fragment hinge region.
A fusion protein comprising consecutive amino acids which, beginning at the amino terminus of the protein, correspond to consecutive amino acids present in (i) alpha-1 antitrypsin or carboxyterminal fragment thereof, (ii) a peptide linker, and (iii) an Fc immune fragment having a deleted or truncated hinge region, wherein the consecutive amino acids (i) remain bound to (iii) when purified.
19-22. (canceled)
28-38. (canceled)
A construct comprising:
- a nucleic acid encoding alpha-1 antitrypsin (AAT) or fragment or peptide cleavage molecule thereof;
- and
- a nucleic acid encoding the amino acid sequence of an Fc fragment wherein the hinge region of the Fc fragment is deleted.
Dependencies are inferred from the claim text.